openPR Logo
Press release

Market Definitions of Bacterial Pneumonia Treatment

07-07-2021 05:25 AM CET | Health & Medicine

Press release from: Transparency Market Research

Global Bacterial Pneumonia Treatment Market: Overview

Bacterial pneumonia is an inflammation of the lungs due to bacterial infection. Pneumonia is a common lung infection where the lung’s air sacks become inflamed. Different types of bacteria can cause pneumonia, but Streptococcus pneumonia and Haemophilus influenza are primarily responsible for most of the bacterial pneumonia. Common indications of bacterial pneumonia include cough, chest pain, shortness of breath, fever, and chills.

Read Report Overview - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=76655

Bacterial pneumonia is caused by bacteria that works its way into the lungs and then multiplies. It can occur on its own or develop after another illness, like a cold or flu. It can enter the lungs through inhalation or through bloodstream. According to the Cleveland Clinics, people who have a weakened immune system as a result of cancer or organ transplant face an increased risk of bacterial pneumonia.

The global bacterial pneumonia treatment market is projected to grow at a significant pace during the forecast period, owing to increase in the rate of incidence of bacterial pneumonia across the globe and continuous R&D activities for the development of vaccines and new drugs for bacterial pneumonia.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=76655

Key Drivers of Global Bacterial Pneumonia Treatment Market

Antibiotics are becoming ineffective against bacterial pneumonia due to increase in resistance of bacteria. Innovations are underway in the pharmaceutical industry in the area of new type of antibiotics candidates. This is expected to increase the rate of cure of bacterial pneumonia in the near future.

Nabriva Therapeutics AG is a biotechnology company involved in the development of pleuromutilins, a new class of antibiotics to treat community-acquired bacterial pneumonia (CABP)

The continuing need of reinventing the drug pipeline, led by bacterial mutation and resistance, presents an opportunity in the global bacterial pneumonia treatment market

Restraints of Global Bacterial Pneumonia Treatment Market

Pathways to the approval for bacterial pneumonia drugs from regulatory bodies have become confusing, generally infeasible, and questionably irrelevant to patients and providers over a period of time. Additionally, scientific and regulatory challenges significantly increase the cost of and time required for drug development, which worsens economic disadvantages of bacterial pneumonia drugs.

In view of the urgency of bacterial drug resistance and the capacity of targeted disease to change rapidly over time, regulatory bodies are not in favor of revision and streamlining of the anti-bacterial drug development and approval process

Request for Analysis of COVID-19 Impact on Bacterial Pneumonia Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=76655

North America to Account for Major Share of Global Bacterial Pneumonia Treatment Market

North America is likely to dominate the global bacterial pneumonia treatment market during the forecast period, due to high rate of incidence of bacterial pneumonia and high awareness about and adoption of new drugs and treatment methods in the region. According to the American Lung Association, Streptococcus pneumonia germ infects over 900,000 people in the U.S. every year.

The bacterial pneumonia treatment market in Asia Pacific is expected to expand at a significant CAGR during the forecast period, owing to rise in the incident rate of pneumonia in countries such as India. According to the World Health Organization (WHO), one in three deaths in India is caused by pneumonia. Pneumonia in India is the leading cause of infant deaths. Every year around 200,000 children aged under five succumb to pneumonia in India.

Pre Book Bacterial Pneumonia Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=76655<ype=S

Key Players Operating in Global Bacterial Pneumonia Treatment Market

Major players operating in the global bacterial pneumonia treatment market are:

Pfizer, Inc.
Teva Pharmaceutical Industries, Ltd.
Lupin Pharmaceuticals, Inc.
Mylan N.V.
Sun Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Sanofi
AstraZeneca plc
Nabriva Therapeutics plc
Others

More Trending Reports by Transparency Market Research –

Medical Imaging Information System Market: https://www.biospace.com/article/medical-imaging-information-system-market-increasing-awareness-among-customers-to-support-market-demand-/

Alpha Mannosidosis Market: https://www.prnewswire.co.uk/news-releases/alpha-mannosidosis-market-to-showcase-9-9-cagr-during-2019-2027-and-reach-us-18-7-mn-valuation-by-2027-says-tmr-811882644.html

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Market Definitions of Bacterial Pneumonia Treatment here

News-ID: 2322696 • Views:

More Releases from Transparency Market Research

Unraveling Cellular Complexity: Single-cell Analysis Market Set for Transformational Growth by 2034
Unraveling Cellular Complexity: Single-cell Analysis Market Set for Transformati …
The Single-cell Analysis Market is entering a phase of explosive expansion driven by rapid advancements in genomics, proteomics, transcriptomics, and precision medicine. With the global industry valued at US$ 3.4 Bn in 2023, demand for advanced tools that enable high-resolution biological insights is accelerating across biotechnology, pharmaceuticals, clinical diagnostics, and academic research. The market is projected to grow at a striking CAGR of 13.9% from 2024 to 2034, ultimately reaching
Sinusitis Treatment Market Expected to Achieve USD 3.5 Billion by 2031 amid Rising Awareness
Sinusitis Treatment Market Expected to Achieve USD 3.5 Billion by 2031 amid Risi …
The Sinusitis Treatment Market has been witnessing significant growth due to the increasing prevalence of sinus infections, rising awareness about respiratory health, and advancements in therapeutic options. Sinusitis, characterized by inflammation of the paranasal sinuses, affects millions globally and can lead to chronic discomfort, reduced productivity, and frequent healthcare visits. The market encompasses various treatment modalities including antibiotics, corticosteroids, decongestants, nasal irrigation devices, biologics, and surgical interventions. The Sinusitis Treatment Market
Slider Zipper Pouch Market Expected to Reach USD 21.1 Billion by 2032 amid E-Commerce Growth
Slider Zipper Pouch Market Expected to Reach USD 21.1 Billion by 2032 amid E-Com …
The Slider Zipper Pouch Market has emerged as a rapidly expanding segment within the flexible packaging industry, driven by rising consumer demand for convenient, resealable, and sustainable packaging formats. Slider zipper pouches are widely used across food, beverages, personal care, pharmaceuticals, household products, and industrial goods to enhance product freshness, increase shelf life, and improve user convenience. Their ease of opening and closing, even for elderly users and children, has
Rising Adoption of Disposable Technologies Fuels the Single-use Bioreactors Market Outlook 2034
Rising Adoption of Disposable Technologies Fuels the Single-use Bioreactors Mark …
The Single-use Bioreactors Market continues to demonstrate strong global momentum, driven by rapid advancements in bioprocessing technologies, increased demand for biologics, and the growing shift from stainless-steel systems to flexible, disposable solutions. With the industry valued at US$ 2.1 Bn in 2023, it is poised for robust expansion, projected to grow at a CAGR of 10.8% from 2024 to 2034, ultimately reaching US$ 6.7 Bn by the end of 2034.

All 5 Releases


More Releases for Bacterial

Prominent Bacterial Conjunctivitis Market Trend for 2025: Innovative Eye Drops T …
What Are the Projected Growth and Market Size Trends for the Bacterial Conjunctivitis Market? The bacterial conjunctivitis market has grown steadily, projected to expand from $4.52 billion in 2024 to $4.76 billion in 2025, at a CAGR of 5.3%. Growth factors include rising bacterial infection cases, improved diagnostics, patient education programs, stringent regulatory frameworks, and physician training. The bacterial conjunctivitis market is projected to grow steadily, reaching $5.54 billion by 2029 at
Community-Acquired Bacterial Pneumonia Market
DelveInsight's "Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Community-Acquired Bacterial Pneumonia market report provides current treatment practices, emerging drugs, Community-Acquired Bacterial Pneumonia market share of the individual therapies, and current
Bacterial Conjunctivitis Drugs Market Report 2018: Segmentation by Disease Type …
Global Bacterial Conjunctivitis Drugs market research report provides company profile for Pfizer Inc., Novartis AG, F. Hoffmann-La Roche, Bayer Healthcare, Valeant Pharmaceutical International Inc., Perrigo Company Plc, Akorn Inc., Santen Pharmaceutical Co. Ltd., Allergan Plc. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth
Bacterial Conjunctivitis Drugs Market: Rising Incidence of Ophthalmic Bacterial …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs is extremely fragmented, leading to commensurate competition among players. The entry barriers faced by new players despite having good research and development capabilities, is lack of capital, Transparency Market Research (TMR) states in its new report on the U.S. market for bacterial conjunctivitis drugs. R&D involves huge costs and this limits the production. Mergers and acquisitions and other forms of strategic alliances can
02-07-2017 | Health & Medicine
TMR
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as